Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

INTRODUCTION: Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based on observational data from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Canonica, Giorgio Walter, Colombo, Giorgio Lorenzo, Rogliani, Paola, Santus, Pierachille, Pitotti, Claudia, Di Matteo, Sergio, Martinotti, Chiara, Bruno, Giacomo Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986414/
https://www.ncbi.nlm.nih.gov/pubmed/32158289
http://dx.doi.org/10.2147/RMHP.S211321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986414/
https://www.ncbi.nlm.nih.gov/pubmed/32158289
http://dx.doi.org/10.2147/RMHP.S211321

Ejemplares similares